India Pharma Outlook Team | Friday, 24 July 2026
Cipla has reported its highest-ever quarterly sales record in India, marking a strong start to Q1 FY27.
The company's domestic business grew 12 percent year-on-year and became the biggest growth driver. Cipla also delivered steady gains across global markets.
Its US opportunity remained a major focus as the company prepares for further expansion in North America. The strong performance came despite a competitive global pharmaceutical environment.
The company reported revenue from operations of Rs. 7,119 crore during the quarter. EBITDA stood at Rs. 1,192 crore, resulting in an EBITDA margin of 16.7 percent. Profit after tax reached Rs. 789 crore, while the PAT margin stood at 11.1 percent.
Achin Gupta, MD and Global CEO, Cipla., said "We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of Rs. 7,119 crore.”
The One India business recorded its best-ever quarterly performance with 12 percent year-on-year growth. The company also improved its chronic portfolio mix to 60.4 percent, reflecting rising demand for long-term therapies.
The Branded Prescription business grew 15.4 percent, outperforming the Indian Pharmaceutical Market by 183 basis points. Strong growth came from respiratory, urology, cardiac, and anti-diabetes therapies.
The Trade Generics business also posted healthy growth. Cipla strengthened this segment through improved distribution and three new product launches during the quarter.
Its Consumer Health business maintained leadership across major categories. Flagship brands including Nicotex, Omnigel, and Cipladine continued holding leading positions in their respective markets.
Also Read: AI-Augmented Clinical Trials & Drug Development Evolution in India
The North America business generated revenue of USD 162 million during the quarter. Cipla expects sequential growth as more products enter the market. Its Albuterol inhaler retained the No. 1 position in the US Albuterol MDI market with a 21 percent market share. The company also started commercial shipments of gVentolin after receiving regulatory approval in the previous quarter. Volumes are expected to increase as supply expands.
Cipla expanded its portfolio through the launches of Nintedanib and Dapagliflozin. These launches strengthen its presence in important therapy segments. Outside North America, the company's international business continued to deliver stable growth. Emerging Markets and Europe generated more than USD 100 million in quarterly revenue. The business grew 5 percent year-on-year in US dollar terms.
In Africa, Cipla retained its No. 2 position in the prescription market. South Africa's private business grew 6.5 percent, ahead of the overall market growth of 5.7 percent.
The company increased R&D spending to Rs. 486 crore, representing 6.8 percent of sales. This marked a 12.3 percent year-on-year increase as Cipla accelerated product development and regulatory filings. Cipla also maintained a strong financial position with a net cash balance of Rs. 9,494 crore. Its debt mainly consisted of lease liabilities and working capital requirements.
Looking ahead, the company plans to expand its presence in key markets. It also aims to strengthen flagship brands, invest in future products, and resolve regulatory priorities. With record domestic sales and a growing global pipeline, Cipla appears well-positioned to sustain growth in the coming quarters.
